28 June-1 July Barcelona
![]() |
![]() |
![]() |
![]() |
1-O | NALIRIFOX versus nab-paclitaxel gemcitabine in treatment-naive patients with mPDAC: additional results from the phase 3 NAPOLI 3 trial | Emma Page | ![]() |
![]() |
|||
1-SO | A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma | NAIMAH BOLAJI | ![]() |
![]() |
|||
1-P | Gastric cancer: Artificial intelligence, complex system analysis and simulation for best management | Oleg Kshivets | ![]() |
![]() |
|||
2-PD | Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies | IRBLleida IRBLleida | ![]() |
![]() |
|||
2-SO | Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with idh1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial | Steve Waye | ![]() |
![]() |
|||
3-SO | Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: preliminary results from the multicenter B-REAL study | Monica Niger | ![]() |
![]() |
|||
4-PD | Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery | Avelyn Wong | ![]() |
![]() |
|||
4-SO | Impact of molecular profiling on survival in patients with advanced biliary tract cancers | Leony Antoun | ![]() |
![]() |
|||
5-SO | Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study | Rebecca Oakes | ![]() |
![]() |
|||
5-PD | MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC) | Maria Alsina | ![]() |
![]() |
|||
5-P | A Soluble resistance related calcium binding protein (Sorcin) up-regulates in the multi-drug resistant advanced gastric cancer patients | Sushmita Ghosh | ![]() |
![]() |
|||
7-PD | Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first line treatment of advanced G/GEJ cancer-updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C | Sue Chen | ![]() |
![]() |
|||
7-P | Change in CA 19-9 after 8 weeks of first-line chemotherapy as a predictor of overall survival in patients with metastatic pancreatic ductal adenocarcinoma | Jarrod Smith | ![]() |
![]() |
|||
8-PD | HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2 advanced stomach Cancer-Correlation of the antibody responses and clinical outcome | Joshua Tobias | ![]() |
![]() |
|||
9-PD | Anti-HER2 therapy following ctDNA-identified ERBB2 amplification for patients with advanced gastric cancer: exploration of real-world outcomes and resistance mechanisms | Sakti Chakrabarti | ![]() |
![]() |
|||
9-O | Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial | Steve Waye | ![]() |
![]() |
|||
10-SO | Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification | Rebecca Oakes | ![]() |
![]() |
|||
11-SO | Bemarituzumab for the Treatment of Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer: Final Analysis of a Randomized Phase 2 Trial (FIGHT) | Utkarsha Singh | ![]() |
![]() |
|||
12-PD | Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort | Marjolein Lansbergen | ![]() |
![]() |
|||
13-SO | Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade | Giovanni Randon | ![]() |
![]() |
|||
13-P | Management of Metastatic Colorectal Cancer in Patients &8805;70 Years - A Single Center Experience | Florian Huemer | ![]() |
![]() |
|||
14-SO | Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age =65 years subgroup | Megan Fox | ![]() |
![]() |
|||
15-PD | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments | Mara Persano | ![]() |
![]() |
|||
16-P | Associations among patient-physician sex concordance, treatment practices, and survival outcomes in a population-based colon cancer cohort | Philip Ding | ![]() |
![]() |
|||
17-P | Impacts of patient-reported non-hormonal symptoms on outcomes of patients with neuroendocrine neoplasms (NENs) | Michael Sawyer | ![]() |
![]() |
|||
17-PD | Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers | Monica NIger | ![]() |
![]() |
|||
19-PD | Finnish population-based metastatic colorectal cancer data collection study - comparison with the prospective RAXO study | Pia Osterlund | ![]() |
![]() |
|||
20-P | Pseudoglandular pattern in hepatocellular neoplasms and its diagnostic value with cytokeratin immunostain | Lee-Ching Zhu | ![]() |
![]() |
|||
21-P | GastroPanel: A blood test to triage dyspeptic patients with atrophic gastritis at risk of developing gastric adenocarcinoma | Cinzia Papadia | ![]() |
![]() |
|||
21-PD | Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients | Martina Carullo | ![]() |
![]() |
|||
22-PD | RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts | Emerik Osterlund | ![]() |
![]() |
|||
22-P | Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency detection and adverse events in patients receiving fluoropyrimidine-based therapy in a pancreatic and biliary tract cancer cohort | Eve Wilson | ![]() |
![]() |
|||
22-SO | Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study | Federica Marmorino | ![]() |
![]() |
|||
23-P | Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP Follow-up Study | Hiroki Sameshima | ![]() |
![]() |
|||
23-SO | The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer | Rachel Purcell | ![]() |
![]() |
|||
25-PD | Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colo-rectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study | Martin Köhler | ![]() |
![]() |
|||
26-PD | Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: a large, multicenter, cohort study | Giacomo Mazzoli | ![]() |
![]() |
|||
27-SO | Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO | Veronica Conca | ![]() |
![]() |
|||
27-PD | The use of pre-operative systemic oxaliplatin or irinotecan doublet chemotherapy in colorectal cancer peritoneal metastases (CRPM): Results from a single UK peritoneal tumour centre | Nadina Tinsley | ![]() |
![]() |
|||
28-P | Locally advanced gastric cancer under FLOT - Real-world data on efficacy of patients with dMMR | Lisa Goncalves | ![]() |
![]() |
|||
28-PD | Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis | ANDRE Thierry | ![]() |
![]() |
|||
31-P | A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors | Maria Apostolopoulou | ![]() |
![]() |
|||
32-SO | Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT) | Marco Germani | ![]() |
![]() |
|||
33-P | The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability | Henian Sun | ![]() |
![]() |
|||
35-P | Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer | Jennifer Humbert | ![]() |
![]() |
|||
48-P | Outcomes of early gall bladder cancer (GBCA): A retrospective analysis from a tertiary care centre in India | Joydeep Ghosh | ![]() |
![]() |
|||
49-P | Stereotactic body radiotherapy (SBRT) for liver metastasis. Institutional experience | Maria Vera Merino | ![]() |
![]() |
|||
51-P | Epigenome-wide DNA methylation profiling identifies the TNXB gene as a potential epigenetic candidate for colorectal cancer prevention | Manuel Macias Gonzalez | ![]() |
![]() |
|||
54-P | Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC) | Francesca Salani | ![]() |
![]() |
|||
56-P | Brightline-2: a Phase IIa/IIb, open-label trial of the MDM2p53 antagonist brigimadlin (BI 907828) in patientswith advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinomaor other ed solid tumours | Teresa Macarulla | ![]() |
![]() |
|||
57-P | Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial | Cinzia Astolfi | ![]() |
![]() |
|||
58-P | An ongoing open-label, phase 2 trial of RP2 or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma | Leilany Lopez | ![]() |
![]() |
|||
60-P | Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial | Ting Liu | ![]() |
![]() |
|||
63-P | Real-world UK retrospective multi-centre review of the use of G-CSF in the prevention of chemotherapy-induced neutropenia in patients with CRC receiving trifluridine/tipiracil | Laura bell | ![]() |
![]() |
|||
67-P | Immune cell and microbiome contributions to radiotherapy response in rectal cancer | Rachel Purcell | ![]() |
![]() |
|||
68-P | Impact of specimens and fixation status on HER2 assessment in the treatment of advanced gastric cancer (HER_WEEKEND study) | Michio Nakamura | ![]() |
![]() |
|||
77-P | Multisite intratumoral chemotherapy improves treatment outcome in a murine model with pancreatic ductal adenocarcinoma | Ron Epelbaum | ![]() |
![]() |
|||
80-P | Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study | Takeshi Yamada | ![]() |
![]() |
|||
82-P | Impact of COVID-19 pandemic on metastatic colorectal cancer outcomes | Mirjana Pavlovic Mavic | ![]() |
![]() |
|||
90-P | Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment | Guglielmo Vetere | ![]() |
![]() |
|||
91-P | Landscape of BRAF-V600E mutant colorectal cancer management in Latin America | Juan Manuel OConnor | ![]() |
![]() |
|||
93-P | Safety and feasibility of irradiation and nivolumab in esophageal cancer a phase I/II study | Geir Olav Hjortland | ![]() |
![]() |
|||
95-P | Long-term effectiveness results and prognostic predictors for overall survival from CIREL the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM | Bleranda Zeka | ![]() |
![]() |
|||
96-P | Circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer treated with multimodal treatment | Lorenzo Gervaso | ![]() |
![]() |
|||
99-P | Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX | Sinead Stewart | ![]() |
![]() |
|||
104-P | Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001) | Huimin Wang | ![]() |
![]() |
|||
105-P | COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study | Steve Waye | ![]() |
![]() |
|||
108-P | An interplay between immune cells and microbiota drives the spontaneous regression of colorectal polyps in familial adenomatous polyposis pig model | Wei Liang | ![]() |
![]() |
|||
110-P | Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis | Maria Bensi | ![]() |
![]() |
|||
112-P | Assessing the accuracy of CT staging for tumor and nodal staging in colon cancer | Jingjing Yu | ![]() |
![]() |
|||
113-P | Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma | Mark Openshaw | ![]() |
![]() |
|||
114-P | The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma | Sabrina Leo | ![]() |
![]() |
|||
116-P | Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC) | James Yu | ![]() |
![]() |
|||
117-P | Feasibility of tumor-informed circulating tumor DNA in neoadjuvant rectal cancer | Charuta Palsuledesai | ![]() |
![]() |
|||
118-P | Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin | Koshiro Fukuda | ![]() |
![]() |
|||
119-P | HGCSG 1803: single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment | Kentaro Sawada | ![]() |
![]() |
|||
120-P | Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: a systematic review and network meta-analysis | Charlene Hoi Lam Wong | ![]() |
![]() |
|||
123-P | CD73high biliary tract cancer (BTC) is a molecularly defined subtype with distinct clinical implications | Pietro Carotenuto | ![]() |
![]() |
|||
126-P | TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: substudies in gastric and colorectal cancer | Sian Budgen | ![]() |
![]() |
|||
131-P | Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma | Roland Eid | ![]() |
![]() |
|||
132-P | Underrepresentation of racial and ethnic minorities in metastatic colorectal carcinoma clinical trials within the United States | Tracey Pu | ![]() |
![]() |
|||
135-P | Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status | Marian Stresko | ![]() |
![]() |
|||
137-P | Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations | Kelly Corona | ![]() |
![]() |
|||
139-P | Total neoadjuvant therapy for locally advanced rectal cancer: a UK cohort | Mayumi Forster | ![]() |
![]() |
|||
142-P | Completion of genetic testing and incidence of pathogenic germline mutation among patients with early-onset colorectal cancer, a single institution retrospective analysis | Zhaohui Jin | ![]() |
![]() |
|||
144-P | Characterisation of gastric tumour microbiota using isolation culture methodology and a novel gastric tumour bioreactor system | Mary Booth | ![]() |
![]() |
|||
146-P | Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: an open-lable, single-arm, phase II study | Huinian Zhou | ![]() |
![]() |
|||
153-P | Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): a retrospective analysis | Francesco Schietroma | ![]() |
![]() |
|||
154-P | Using the EVendo score to predict varices and varices needing treatment in hepatocellular carcinoma patients planned for atezolizumab-bevacizumab | Ching Han Toh | ![]() |
![]() |
|||
156-P | Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: a prospective, multicenter, open-label, single-arm phase II study | Bo Long | ![]() |
![]() |
|||
158-P | The algorithm of esophagectomy technique ion in surgical treatment of squamous cell carcinoma and adenocarcinoma of esophagus | Nikolay Khandogin | ![]() |
![]() |
|||
159-P | Association of acrochordons and colorectal polyps: a pilot study to identify potential genetic or viral etiology | Bogdan Gafton | ![]() |
![]() |
|||
162-P | Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): a retrospective exploratory study | Jing Huang | ![]() |
![]() |
|||
164-P | Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POL?)-mutated solid tumours in the GARNET study | Steve Orlando | ![]() |
![]() |
|||
167-P | Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: preliminary results of the Italian, observational PANCAKE study | Federico Nichetti | ![]() |
![]() |
|||
172-P | VOLTAGE cohort D: preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer | Yusuke Takahashi | ![]() |
![]() |
|||
173-P | Extended molecular profiling in patients with biliary tract cancers: impact of the brcaness phenotype in patients management | Virginia Genovesi | ![]() |
![]() |
|||
174-P | Outcomes in local gastric cancer resected without neoadjuvant therapy: a descriptive study | Elisabet Bujons Buscarons | ![]() |
![]() |
|||
175-P | Next-generation sequencing in colorectal cancer patients: characterization and prognostic implications | Federico Longo | ![]() |
![]() |
|||
177-P | Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: the ERCOLE study | Maria Alessandra Calegari | ![]() |
![]() |
|||
180-P | Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: real-world data | Sofia Montenegro Luis | ![]() |
![]() |
|||
181-P | Adoption of neoadjuvant immunotherapy in patients with deficient mismatch repair localized colorectal cancer: a National Cancer Database analysis | Sakti Chakrabarti | ![]() |
![]() |
|||
182-P | Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer | Rafael Rafael | ![]() |
![]() |
|||
183-P | BRAF mutant metastatic colon cancer expect the unexpected: a single centre study | Mona Hassan | ![]() |
![]() |
|||
186-P | Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer | Mariam Manukyan | ![]() |
![]() |
|||
187-P | Targeting glutamine metabolism and EGFR in RAS wildtype metastatic colorectal cancer | Kristen Ciombor | ![]() |
![]() |
|||
189-P | Surrogate endpoints in advanced gastroesophageal cancer: a systematic review and meta-analysis of phase III clinical trials | IRBLleida IRBLleida | ![]() |
![]() |
|||
190-P | NALIRIFOX (liposomal irinotecan 5&8209;fluorouracil/leucovorin oxaliplatin) versus FOLFOX (5&8209;fluorouracil/leucovorin oxaliplatin) as first-line treatment of metastatic pancreatic ductal adenocarcinoma: real-world comparative overall survival analysis | Emma Page | ![]() |
![]() |
|||
195-P | Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: a multicenter retrospective real-world study | Carlo Signorelli | ![]() |
![]() |
|||
197-P | Clinical outcomes in patients with krukenberg tumors from colorectal cancer | Arsha Ostowari | ![]() |
![]() |
|||
202-P | Topical diclofenac in prevention of capecitabine associated HFS in patients with GI cancers: an exploratory subgroup analysis of the D-ToRCH study | Akhil Santhosh | ![]() |
![]() |
|||
205-P | Streamlining the diagnostic pathway for Lynch Syndrome in colorectal cancer patients: a ten-year experience in a single Italian center | Alberto Puccini | ![]() |
![]() |
|||
207-P | Analysis of chemotherapy-induced subtype shifts in patient-derived tumoroids and parallels to functional in-vitro chemosensitivity testing in pancreatic ductal adenocarcinoma | Tabea Sturmheit | ![]() |
![]() |
|||
210-P | Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer | Mohamed Aseafan | ![]() |
![]() |
|||
218-P | Oligometastatic Pancreatic Cancer: A Systematic Review and Synthesis of Consensus | Carl-Stephan Leonhardt | ![]() |
![]() |
|||
219-P | Non-operative management of localized mismatch repair deficient colon cancer: a real-world perspective | Sakti Chakrabarti | ![]() |
![]() |
|||
220-P | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: a meta-analysis | John Kelvin Lalusis | ![]() |
![]() |
|||
221-P | Prediction of colon cancer recurrence based on proteomic biomarkers | Soledad Cameselle-Garcia | ![]() |
![]() |
|||
231-P | Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2) | Benjamin Weinberg | ![]() |
![]() |
|||
232-P | The predictive factors for identifying gastric cancer in patients with gastric indefinite for neoplasia lesions | Hye-Su You | ![]() |
![]() |
|||
233-P | Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: a single-center study, updated with new data | Stefani Ioannou | ![]() |
![]() |
|||
235-P | Association of stage shift and prior gastroscopy in patients with gastric cancer | Yi-Hsin Yang | ![]() |
![]() |
|||
236-P | Aflibercept-based and bevacizumab-based second line regimens in patients with RAS mutant metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort | Jessica Lucchetti | ![]() |
![]() |
|||
240-P | Frequency and management of trifluridine/tipiracil (FTD/TPI) bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice | Nieves Martínez Lago | ![]() |
![]() |
|||
245-P | Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma | Joris Jaekers | ![]() |
![]() |
|||
249-P | Aflibercept-based and bevacizumab-based second line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort | Lorenzo Angotti | ![]() |
![]() |
|||
251-P | Prospective validation of the Asian Pacific Colorectal Screening (APCS) score to detect colorectal neoplasia among Mexican subjects undergoing screening colonoscopy | Monica Meneses-Medina | ![]() |
![]() |
|||
252-P | Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer | Kotaro Takeshita | ![]() |
![]() |
|||
253-P | Single agent immunotherapy in advanced oesophago-gastric (OG) cancer: an option for frail patients | Grisma Patel | ![]() |
![]() |
|||
256-P | Albumin-bilirubin (ALBI) grade at 6 weeks post-diagnosis is a better prognosticator than baseline ALBI in intrahepatic cholangiocarcinoma | Chi Fung Wong | ![]() |
![]() |
|||
263-P | Epidemiology and characteristics of low or normal AFP vs high AFP in hepatocellular carcinoma- retrospective experience in a tertiary care institute | ANAND PRAVEEN KUMAR A | ![]() |
![]() |
|||
266-P | Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI) | Darren Cowzer | ![]() |
![]() |
|||
267-P | Spatially resolved detection of premalignant lesions and immune-infiltration in gastric endoscopic biopsies using multiplexed immunofluorescence and correlation with OLGA/OLGIM assessment | Franz Villarroel-Espindola | ![]() |
![]() |
|||
268-P | Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer | Stefania Napoli | ![]() |
![]() |
|||
272-P | Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune check-point inhibitor (ICI) therapy | James Harding | ![]() |
![]() |
|||
273-P | Genomic alterations associated with aggressive histology and decreased overall survival in neuroendocrine malignancies | Nicole Farha | ![]() |
![]() |
|||
275-P | FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers | Federico Nichetti | ![]() |
![]() |
|||
276-P | Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during covid-19 pandemic | razia aslam | ![]() |
![]() |
|||
277-P | Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: the EPIC trial | Antía Cousillas Castiñeiras | ![]() |
![]() |
|||
278-P | Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC) | Alejandra Romano | ![]() |
![]() |
|||
281-P | Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer | Angélique Vienot | ![]() |
![]() |
|||
282-P | Atezolizumab and bevacizumab in the treatment of advanced hepatocellular carcinoma - a single-center experience | Nika Librenjak | ![]() |
![]() |
|||
284-P | Stereotactic body radiotherapy (SBRT) for liver metastasis of colorectal and anal cancer patients: clinical outcomes of a single centre experience | Berta Martin-Cullell | ![]() |
![]() |
|||
285-P | Basket trials in upper gastrointestinal and hepato-pancreatico-biliary cancers an emerging entity | Prerana Huddar | ![]() |
![]() |
|||
287-P | Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions | Elena Garcia Arcelay | ![]() |
![]() |
|||
290-P | Treatment sequences and locoregional therapies for patients with carcinoid and refractory carcinoid syndrome. A multicentric cohort analysis | ANA ISABEL OVIEDO ALBOR | ![]() |
![]() |
|||
291-P | Missing colorectal liver metastases after neoadjuvant chemotherapy: can we improve the prognosis? | Elena Fernandez de Sevilla | ![]() |
![]() |
|||
294-P | The outcome of patients with mismatch repair deficient esophagogastric cancer receiving immunotherapy: A systematic review | Sakti Chakrabarti | ![]() |
![]() |
|||
300-P | Progression free survival in patients with metastatic colorectal cancer treated with maintenance therapy with bevacizumab adjusted by sideness in a third level hospital in Mexico City | ABDEL KARIM DIP BORUNDA | ![]() |
![]() |
|||
307-P | Serial ctDNA monitoring during immunotherapy (IO) in patients (pts) with MSI-H/dMMR advanced colorectal cancer (CRC) | Shoshana Mehler | ![]() |
![]() |
|||
311-P | Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population in United States | Lekha Yadukumar | ![]() |
![]() |
|||
313-P | Impact of COVID-19 on national trends of hospitalization and outcomes in pancreatic cancer patients presenting with venous thromboembolism in the United States | Lekha Yadukumar | ![]() |
![]() |
|||
316-P | A retrospective study of gemcitabine with nab-paclitaxel as third line retreatment in advanced pancreatic adenocarcinoma | Tara McSweeney | ![]() |
![]() |
|||
320-P | Immune checkpoint inhibitors (ICIs) vs chemotherapy as 3rd line regimen in patients with advanced gastric or esophageal (G/E) adenocarcinoma: A comparative study | Brooke Wietharn | ![]() |
![]() |
|||
327-P | Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma | Kreina Sharela Vega-Cano | ![]() |
![]() |
|||
330-P | ERBB2 mutations in metastatic colorectal cancer: from clinicopathological features to potential treatment implications in a real-world cohort | caterina vaghi | ![]() |
![]() |
|||
332-P | Characteristic and clinical outcome of localized gastric cancer; real-world data | Amal AlJuhani | ![]() |
![]() |
|||
333-P | Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer | Yana Chikhareva | ![]() |
![]() |
|||
336-P | Neoadjuvant chemotherapy of the mFOLFIRINOX in the treatment of resectable pancreatic cancer | Dayana Kantieva | ![]() |
![]() |
|||
337-P | Associate factors for endoscopic submucosal disection and postoperative delayed hemorrhage of colorectal neoplasm. | Yong Wook Jung | ![]() |
![]() |
|||
338-P | Second line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first line treatment with gemcitabine and nab-paclitaxel | Tara McSweeney | ![]() |
![]() |
|||
342-P | Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria | Ragini Khajuria | ![]() |
![]() |
|||
349-P | An evidence-based patient resource program to improve the everyday lives of patients with metastatic gastrointestinal cancer | Alberto Sobrero | ![]() |
![]() |
|||
360-P | Efficacy of regorafenib according to extended RAS evaluation: a multicenter retrospective analysis | Giovanni Trovato | ![]() |
![]() |
|||
368-P | Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: a multicenter retrospective analysis | Giulia Caira | ![]() |
![]() |
|||
374-P | Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy | Sven Van Laere | ![]() |
![]() |
|||
376-P | CoVigi Phase IV multicentric trial evaluating Covid-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2 specific antibody and T-cell response focused on patients with gastrointestinal tumors | Radka Obermannova | ![]() |
![]() |
|||
378-P | Single institute experience of peri-operative FLOT chemotherapy | Vikram Bansal | ![]() |
![]() |
|||
379-P | ARID1A as a prognostic biomarker in gastroesophageal cancer: a genomic database analysis | Annalisa Schirizzi | ![]() |
![]() |
|||
380-P | Real world survival outcome in gastric cancer in a resource limited setting - an Indian experience | Ruhi Kumar | ![]() |
![]() |
|||
381-P | Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): a single institution analysis | Giustina Valente | ![]() |
![]() |
|||
386-P | Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer | Mounia Foucart | ![]() |
![]() |
|||
397-P | Progression-free survival with maintenance therapy with fluoropyrimidine in patients with advanced gastric and gastroesophageal junction cancer in a third level hospital in Mexico City | Alberto Pimentel | ![]() |
![]() |
|||
402-P | Six-months CA19.9 velocity as a predictive factor for relapse-free survival after curative pancreasectomy in pancreatic cancer | Silvia Cesario | ![]() |
![]() |
|||
403-P | Rectal cancer in young patients - single center experience | Vanessa Patel | ![]() |
![]() |
|||
408-P | Costa Rica, an example of the Americas in the implementation of an innovative organized colorectal screening program during 2017 2022 | Jeffrey Jacobo | ![]() |
![]() |
|||
410-P | Factors affecting progression free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines | Evgenia Kuzmina | ![]() |
![]() |
|||
411-P | Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment | Lynne Kelley | ![]() |
![]() |
|||
415-P | The importance of RAS and BRAF in metastatic colorectal cancer - real world evidence from North-East Romania | Vlad Afrasanie | ![]() |
![]() |
|||
419-P | Safety and effectiveness analysis of neoadjuvant chemoradiation plus consolidative chemotherapy with concurrent anti-pd-1 therapy in mid-low locally advanced rectal cancer | Xinliang Liu | ![]() |
![]() |
28 June-1 July Barcelona
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|